comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 22:24:57 - browse：3

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Why rehabilitation engineers need to center patients in their research

hotspot

WSS

Q&A: Jennifer Adair on making gene therapy available globally

Getting Alzheimer's drug Leqembi to patients can be a challenge

As digital health tech proliferates, a new institute aims to cut through hype

Key Senate committee drafts bipartisan bill to stem drug shortages

Bird flu outbreak in cows is latest avian flu curveball

Cosmetics set for new safety regulation. Why the industry is on board

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

explore

Wildfire smoke exposes gaps in outdoor worker protections

Medicare has a new plan to address drug shortages

Peter Hotez and the public health issue of online harassment

A public scorecard can help hold safety

Sports medicine is finally prioritizing gender equality

Key House panel plots a new health care package

Drug repurposing or repositioning? The language matters

Dogs on Prozac: What pet anti

Hollywood unions extend contract negotiations for actors

At Orexo, a ‘turning point’ for everything but digital health

entertainment

Health care needs a new profession: neuroimaging counseling

Why rehabilitation engineers need to center patients in their research

Dogs on Prozac: What pet anti

Medicare has a new plan to address drug shortages

At Orexo, a ‘turning point’ for everything but digital health

After traumatic brain injury, life support decisions can use more time

knowledge

Wikipedia

hotspot

focus